Journal Information
Vol. 29. Issue 6.
Pages 264-269 (August - September 1993)
Share
Share
Download PDF
More article options
Vol. 29. Issue 6.
Pages 264-269 (August - September 1993)
Full text access
Daño pulmonar difuso en la rata por la administración endovenosa del factor activador plaquetario
Diffuse pulmonary damage by intravenous administration of the platelet activator factor to the rat
Visits
3230
E. Novoa, G. Arenas
Departamentos de Medicina Experimental Norte, Facultad de Medicina, Universidad de Chile, Santiago, Chile
G. Varas*, M.E. Lathrop*, M.J. Oyarzún*
* Ciencias Preclínicas Oriente. Facultad de Medicina, Universidad de Chile, Santiago, Chile
This item has received
Article information
Abstract
Bibliography
Download PDF
Statistics

El factor activador plaquetario (PAF) ha sido propuesto como un posible intermediario en la patogénesis del síndrome de distrés respiratorio del adulto (SDRA).

Nuestro objetivo fue evaluar el papel del PAF como mediador de daño pulmonar y su efecto sobre el contenido de surfactante alveolar de ratas al ser administrado por vía endovenosa.

Se administró 8 μg de PAF/kg de peso corporal a 21 ratas Wistar de peso promedio 254±55 g (DS), sacrificadas al cabo de 1-4 y 24 horas. Como controles se utilizaron ratas sacrificadas en iguales tiempos, pero tratadas con NaCl 0,9% ev. En el lavado broncoalveolar (LBA) se determinó contenido de proteínas, fosfolípidos totales (PLT), fostatidilcolina disaturada (DSPC), recuento celular y actividad de las enzimas fosfatasa alcalina (F.Alc) y gama-glutamiltranspeptidasa (GGT). En cada serie se efectuó un estudio histológico y determinación de gases en sangre arterial antes y después de la administración de PAF.

La administración de PAF provocó una disminución del contenido de PLT y de DSPC que fue significativa (p < 0,05) al cabo de 1 y 4 horas. A las 4 horas hubo aumento del recuento celular del LBA, hiperventilación y lesiones histológicas leves. No se observaron cambios en el contenido de proteínas, ni en la actividad enzimática en ninguna de las series tratadas con PAF.

El PAF administrado por vía endovenosa en la rata, produce una disminución del contenido de surfactante alveolar, hecho que se acompaña de lesiones pulmonares leves aunque difusas.

The platelet activator factor (PAF) has been postulated as a likely mediator in the pathogenesis of adult respiratory distress syndrome (ARDS).

The aim of the present study was to assess the role of PAF as a mediator of pulmonary damage and its effect on alveolar surfactant content.

The effect of intravenous perfusion of PAF (8 μg/kg of body weight) was studied in 21 Wistar rats, with an average weight of 254±55g (SD). This serie was compared with control rats injected with NaCl 0.9% solution, at the end of 1-4 and 24 hours respectively. Total proteins, total phospholipid (TPL), disaturated phosphatidylcholine (DSPC), cell counting and enzymatic activity: alkaline phosphatase (P.alc) and gammaglutamyltranspeptidase (GGT) were analyzed in the bronchoalveolar lavage (BAL). In each experimental series an histologic study and determinations of arterial blood gases before and after the intravenous administration of PAF were carried out.

The administration of PAF caused a decrease of TPL and DSPC contents at the end of 1 and 4 hours (p < 0.05). An increase in cell counting, hyperventilation and slight histologic lesions of the lung 4 hours after administering PAF were also observed. However, none significant changes were found in these experiments in total proteins ñor in enzymatic activity from bronchoalveolar lavage.

It is concluded that the intravenous administration of PAF in rats produced a decrease in the alveolar surfactant content which was associated to slight but diffuse pulmonary lesions.

Full text is only aviable in PDF
Bibliografía
[1.]
L.M. McManus, S.I. Deavers.
Platelet activating factor in pulmonary pathobiology.
Clin Chest Med, 10 (1989), pp. 107-118
[2.]
K.R. Stenmark, M. Eyzaguirre, J.Y. Wescott, P.M. Henson, R.C. Murphy.
Potential role of eeicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia.
Am Rev Respir Dis, 136 (1987), pp. 770-788
[3.]
D.J. Hanahan.
Platelet activator factor: A biologically active phosphoglyceride.
Ann Rev Biochem, 55 (1986), pp. 483-509
[4.]
B. Arnoux, D. Duval, J. Benveniste.
Release of platelet activator factor (PAF-acether) from alveolar macrophages by tha calcium ionophore A23187 and phagocytosis.
Eur J Clin Invest, 10 (1980), pp. 437-441
[5.]
R. Rylander, L. Beijer.
Inhalation of endotoxin stimulates alveolar macrophage production of platelet-activating factor.
Am Rev Respir Dis, 135 (1987), pp. 83-86
[6.]
M.C. Prevost, C. Cariven, M.F. Simon, H. Chap, L. Douste-Blazy.
Platelet-activating factor (PAF-acether) is released into rat pulmonary alveolar fluid as a consequence of hypoxia.
Biochem Biophys Res Commun, 119 (1984), pp. 58-63
[7.]
R.J. King, R. Kumar, H.M. Martin, D.J. Hanahan.
Platelet activating factor (PAF) stimulates the secretion of surfactant by rat type II cells with the same increment and time course as tetradecanol phorbol acetate (TPA).
Fed Proc, 45 (1986), pp. 1530
[8.]
R.J. King, H. Martin, R. Kumar, D.J. Hanahan.
Platelet activator factor (PAF) stimulates the metabolism of intracellular and alveolar pool of disaturated phosphatidylcholine (DSPC) in rat lung when tested in vivo.
Am Rev Respir Dis, 135 (1987), pp. 376
[9.]
E.G. Bligh, W.J. Dyer.
A rapid method of total lipid extraction and purification.
Can J Biochem, 37 (1959), pp. 911-917
[10.]
G.R. Bartlett.
Phosphorus assay in column chromatography.
J Biol Chem, 234 (1959), pp. 466-468
[11.]
R.J. Mason, J. Nellehnbogen, J.A. Clements.
Isolation of disaturated phosphatidylcholine with osmium tetroxide.
J Lipid Res, 17 (1976), pp. 281-284
[12.]
O.H. Lowry, N.J. Rosebrough, A.L. Farr, E.J. Randall.
Protein measurement with the folin phenol reagent.
J Biol Chem, 193 (1951), pp. 265-275
[13.]
J. Puente.
Gamma-glutamiltranspeptidasa y metabolismo del glutation en glándula mamaria e hígado de rata.
Tesis para optar al grado de Doctor en Bioquímica, Facultad de Ciencias Químicas y Farmacéuticas, Universidad de Chile, (1985),
[14.]
O.A. Bessey, O.H. Lowry, M.J. Brock.
A method for the rapid determination of alkaline phosphatase with five cubic milimeters of serum.
J Biol Chem, 164 (1946), pp. 321-329
[15.]
R. Mendoza, M. Capetillo, M.E. Lathrop, M.J. Oyarzún.
Intoxicación experimental por paraquat: Correlación entre el recuento celular diferencial del lavado broncoalveolar y la histopatología pulmonar.
Enf Respir Cir Torac, 6 (1990), pp. 4-10
[16.]
J.H. Zar.
Multiple comparisons. En: Biostatistical analysis.
2nd ed, Prentice Hall Inc, (1984), pp. 185-205
[17.]
M. Criscuoli, A. Subissi.
PAF-acether-induced death in mice: involvement of arachidonate metabolites and beta-adrenoceptors.
Br J Pharmac, 90 (1987), pp. 203-209
[18.]
D.M. Stafforini, S.M. Prescott, T.M. McIntyre.
Purification of human plasma platelet activating factor acetylhydrolase.
Fed Proc, 45 (1986), pp. 1.530
[19.]
R.W. Wilcox, R.L. Wykle, J.D. Schmitt, L.W. Daniel.
The degradation of platelet-activating factor and related lipids: Susceptibility to phospholipases C and D.
Lipids, 22 (1987), pp. 800-807
[20.]
K.M. Moser.
Pulmonary embolism.
Am Rev Respir Dis, 115 (1977), pp. 829-852
[21.]
A. Baritussio, J.A. Clements.
Acute effects of pulmonary artery occlusion on the pool of alveolar surfactant.
Respir Physiol, 45 (1981), pp. 323-331
[22.]
D.H. Namm, A.S. Tadepalli, J.A. High.
Species specificity of the platelet responses to l-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine.
Thromb Res, 25 (1982), pp. 341-350
[23.]
R.H. Perelman, P.M. Farrell, M.J. Engle, J.W. Kemnitz.
Developmental aspects of lungs lipids.
Ann Rev Physiol, 47 (1985), pp. 803-822
Copyright © 1993. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?